Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Green

Showing results (881-890 of 964) with videos related to

Pageof 97
Sort By:
British Journal of Haematology|August 29, 1998
Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Blood|December 3, 1998
Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Schizophrenia Bulletin|November 7, 2017
Episodic Memory for Dynamic Social Interaction Across Phase of Illness in SchizophreniaJunghee Lee, Keith H Nuechterlein, Barbara J Knowlton, et al.
Cancer Discovery|July 12, 2022
AACR Project GENIE: 100,000 Cases and BeyondTrevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
Frontiers in Drug Discovery|March 3, 2022
Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and ParkinsonismChristopher R Apostol, Kelsey Bernard, Parthasaradhireddy Tanguturi, et al.
Journal for Immunotherapy of Cancer|December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discoveryElizabeth M Will, Benjamin F Green, Scott Carey, et al.
Schizophrenia Research|August 20, 2018
Social vs. non-social measures of learning potential for predicting community functioning across phase of illness in schizophreniaPeter E Clayson, Robert S Kern, Keith H Nuechterlein, et al.
Frontiers in Oncology|October 23, 2024
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapyKamal S Saini, Sasikala Somara, Heidi C Ko, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 14, 2020
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteersJoshua T Kantrowitz, Jack Grinband, Donald C Goff, et al.
Molecular Cancer Therapeutics|October 22, 2017
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationGenshi Zhao, Colin F Green, Yu-Hua Hui, et al.
Pageof 97

Showing results (881-890 of 964) with videos related to

Sort By:
Pageof 97
British Journal of Haematology|August 29, 1998
Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Blood|December 3, 1998
Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemiaC J Knechtli, N J Goulden, J P Hancock, et al.
Schizophrenia Bulletin|November 7, 2017
Episodic Memory for Dynamic Social Interaction Across Phase of Illness in SchizophreniaJunghee Lee, Keith H Nuechterlein, Barbara J Knowlton, et al.
Cancer Discovery|July 12, 2022
AACR Project GENIE: 100,000 Cases and BeyondTrevor J Pugh, Jonathan L Bell, Jeff P Bruce, et al.
Frontiers in Drug Discovery|March 3, 2022
Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and ParkinsonismChristopher R Apostol, Kelsey Bernard, Parthasaradhireddy Tanguturi, et al.
Journal for Immunotherapy of Cancer|December 25, 2025
AstroID resource: a scalable, relational database structure for longitudinal biomarker discoveryElizabeth M Will, Benjamin F Green, Scott Carey, et al.
Schizophrenia Research|August 20, 2018
Social vs. non-social measures of learning potential for predicting community functioning across phase of illness in schizophreniaPeter E Clayson, Robert S Kern, Keith H Nuechterlein, et al.
Frontiers in Oncology|October 23, 2024
Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapyKamal S Saini, Sasikala Somara, Heidi C Ko, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 14, 2020
Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacoBOLD in healthy volunteersJoshua T Kantrowitz, Jack Grinband, Donald C Goff, et al.
Molecular Cancer Therapeutics|October 22, 2017
Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid CoadministrationGenshi Zhao, Colin F Green, Yu-Hua Hui, et al.
Pageof 97